Literature DB >> 5808572

L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism.

W Weiner, W Harrison, H Klawans.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 5808572     DOI: 10.1016/0024-3205(69)90428-7

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


× No keyword cloud information.
  11 in total

1.  Approaches to the study of cerebral dopamine metabolism in certain extrapyramidal diseases.

Authors:  V P Barkhatova; E I Kandel'; E G Demina
Journal:  Neurosci Behav Physiol       Date:  1985 Mar-Apr

2.  On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.

Authors:  C Casati; A Agnoli; A Jori; E Dolfini
Journal:  Z Neurol       Date:  1973-04-02

3.  Observations on the dopaminergic nature of hyperthyroid chorea.

Authors:  H L Klawans; D M Shenker
Journal:  J Neural Transm       Date:  1972       Impact factor: 3.575

Review 4.  Clinical pharmacokinetics of levodopa in parkinson's disease.

Authors:  J R Bianchine; G M Shaw
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

Review 5.  Current concepts of Parkinsonism.

Authors:  J Pearce; I Pearce
Journal:  Postgrad Med J       Date:  1971-12       Impact factor: 2.401

6.  Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease.

Authors:  W J Weiner; H L Klawans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-10       Impact factor: 10.154

7.  L-dopa in Parkinsonism associated with cerebellar dysfunction (probable olivopontocerebellar degeneration).

Authors:  H L Klawans; E Zeitlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-02       Impact factor: 10.154

8.  Biotransformation of L-dopa in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study.

Authors:  S Sarre; P Herregodts; D Deleu; A Devrieze; N De Klippel; G Ebinger; Y Michotte
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-09       Impact factor: 3.000

9.  Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF.

Authors:  R B Godwin-Austen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-06       Impact factor: 10.154

10.  Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.

Authors:  H L Klawans; S P Ringel; D M Shenker
Journal:  J Neurol Neurosurg Psychiatry       Date:  1971-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.